LLY
The next Ozempic-style drama
Eli Lilly just dropped the kind of trial update that makes obesity-drug investors sit up straighter. The company said its experimental triple-hormone agonist, retatrutide, met the primary endpoints in two pivotal Phase 3 studies, with patients losing serious weight while also improving diabetes and cardiovascular markers.
Why this matters to your portfolio
This isn’t just “people lost weight” news. Lilly is trying to turn retatrutide into a once-weekly drug that hits three hormone receptors at once — GIP, GLP-1, and glucagon — which is pharma-speak for “we’re trying to build a more powerful all-in-one metabolic machine.” In TRIUMPH-2, patients with type 2 diabetes and obesity saw better glycemic control and major weight loss over 80 weeks, while TRIUMPH-3 showed meaningful drops in weight and heart-risk markers for people with severe obesity and established cardiovascular disease.
The numbers doing the heavy lifting
The headline figures are chunky enough to get Wall Street’s attention:
- In TRIUMPH-2, average weight loss reached as much as 49.6 pounds depending on dose.
- A1C fell by up to 1.6%, which is the kind of diabetes improvement doctors and investors both notice.
- In TRIUMPH-3, the top dose cut triglycerides by 37% and systolic blood pressure by 9.3 mmHg.
- Lilly also said it’s preparing manufacturing data for a Biologics License Application, with a U.S. filing targeted for the first quarter of 2027.
The fine print, because pharma never lets you have nice things
The catch is timing. Retatrutide is still investigational, and Lilly’s premarket stock dip suggests the market wasn’t exactly throwing confetti. But if the drug keeps clearing regulatory hurdles, Lilly could end up with another heavyweight in the GLP-1-adjacent arms race — and that’s a very crowded, very lucrative neighborhood.
Big picture: Lilly is trying to prove it can do more than ride the obesity wave. It wants to own it.